Wendy Stock to Molecular Targeted Therapy
This is a "connection" page, showing publications Wendy Stock has written about Molecular Targeted Therapy.
Connection Strength
1.213
-
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 01 08; 3(1):96-104.
Score: 0.549
-
Novel drug targets in acute leukemia. Clin Adv Hematol Oncol. 2015 Aug; 13(8):493-5.
Score: 0.433
-
Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML. Oncology (Williston Park). 2017 Mar 15; 31(3):190, 192.
Score: 0.121
-
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015 Oct 20; 6(32):33410-25.
Score: 0.110